ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVAX Novavax Inc

13.09
-1.31 (-9.10%)
18 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.31 -9.10% 13.09 13.09 13.10 14.38 12.95 14.34 13,906,467 00:59:38

Novavax to Present at the 27th Annual Piper Jaffray Healthcare Conference

24/11/2015 9:05pm

GlobeNewswire Inc.


Novavax (NASDAQ:NVAX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novavax Charts.

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference.

Conference details are as follows:

Date: Tuesday, December 1, 2015Time: 2:00 p.m. U.S. Eastern TimeLocation: New York Palace Hotel, New York CityLive webcast: http://edge.media-server.com/m/p/ui3ne8dn

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.

Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart